Entod Pharmaceuticals, a Mumbai-based pharmaceutical company, has announced the development of the world's first human insulin eye drops, EyeSulin, designed to treat corneal eye conditions. The company plans to initiate the regulatory approval process in India, seeking approval from the Central Drugs Standard Control Organization (CDSCO) for clinical trials and subsequently from the Drug Controller General of India (DCGI) for commercialization.
Entod Pharmaceuticals' CEO, Nikkhil K Masurkar, highlights the potential of insulin eye drops to revolutionize ophthalmic therapeutics. Upon regulatory clearance, the company aims to produce EyeSulin under the Make in India initiative, making it accessible and affordable both in India and globally.
Bharati S Jadhav, Senior Scientific Manager at Entod Pharmaceuticals, emphasizes the challenges and expertise involved in developing human insulin eye drops. The company has formulated three different strengths of EyeSulin to facilitate a comprehensive clinical evaluation.
Entod Pharmaceuticals has previously developed PresVu eye drops for presbyopia, which is awaiting approval from the DCGI for commercialization.